Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Assets (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Assets for 9 consecutive years, with $668.2 million as the latest value for Q4 2025.

  • Quarterly Assets fell 10.28% to $668.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $668.2 million through Dec 2025, down 10.28% year-over-year, with the annual reading at $668.2 million for FY2025, 10.28% down from the prior year.
  • Assets hit $668.2 million in Q4 2025 for Protagonist Therapeutics, down from $701.7 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $744.7 million in Q4 2024 to a low of $239.9 million in Q1 2023.
  • Historically, Assets has averaged $464.1 million across 5 years, with a median of $365.6 million in 2021.
  • Biggest five-year swings in Assets: crashed 31.13% in 2023 and later skyrocketed 162.35% in 2024.
  • Year by year, Assets stood at $347.7 million in 2021, then decreased by 28.69% to $247.9 million in 2022, then soared by 44.38% to $358.0 million in 2023, then skyrocketed by 108.05% to $744.7 million in 2024, then fell by 10.28% to $668.2 million in 2025.
  • Business Quant data shows Assets for PTGX at $668.2 million in Q4 2025, $701.7 million in Q3 2025, and $718.0 million in Q2 2025.